Effect of adjuvant lithium on thyroxine (T4) concentration after radioactive iodine therapy

Hammond, Emmanuel Niiboye; Vangu, Mboyo-Di-Tamba

doi:10.1007/s00259-016-3388-3

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be considered as a temporizing or adjuvant therapy for hyperthyroidism. Treatment with lithium prevents serum thyroid hormone increase after ATD withdrawal and RAI therapy in GD [55,56], and it has also been used to control hyperthyroidism when ATD is not tolerated [57]. However, due to risk of arrhythmia, diabetes insipidus, skin abnormalities and multiple neurologic side effects, lithium treatment is rarely employed.…”

Section: Lithiummentioning

confidence: 99%

Current and Future Treatments for Graves’ Disease and Graves’ Ophthalmopathy

Kotwal

Stan

2018

Horm Metab Res

View full text Add to dashboard Cite

The course and pathogenesis of Graves’ disease and Graves’ ophthalmopathy are interdependent, influencing each other’s therapeutic choices. Multiple factors including geographic location, access to medical services, patient and physician preferences influence the management of these conditions. Graves’ disease is classically managed with one of three treatment options – antithyroid drugs, radioactive iodine, and thyroidectomy. In recent years, there has been a shift towards antithyroid drugs, including long term therapy with these agents, given the advantage of avoiding hypothyroidism and the apparent safety of this approach. In addition, new therapies are (slowly) emerging, focusing on immunomodulation. Technological advances are opening doors to non-pharmaceutical interventions that aim to deal with both structural thyroid abnormalities as well as biochemical abnormalities of hyperthyroidism. Graves’ ophthalmopathy management is guided by its activity and severity status, with treatment options including smoking cessation, control of hyperthyroidism, local eye measures, glucocorticoids, selenium, orbital radiotherapy, and surgery. In addition to these established treatment choices, new immunotherapy-based approaches are being tested. Some of them (tocilizumab and teprotumumab) are very promising but further evaluation is needed before we can establish their role in clinical care. Agents identified as beneficial in Graves’ disease management will likely be tested in Graves’ ophthalmopathy as well. In the coming years, our main clinical responsibility will be to find the proper balance between the benefits and potential risks of these incoming therapies, and to identify the subgroups of patients where this ratio is most likely to favor a safe and successful therapeutic outcome.

show abstract

Section: Lithiummentioning

confidence: 99%

Current and Future Treatments for Graves’ Disease and Graves’ Ophthalmopathy

Kotwal

Stan

2018

Horm Metab Res

View full text Add to dashboard Cite

show abstract

“…Moreover, the possibility of its use in other pathological states has been reported, e.g. as an adjuvant in the cure of leukaemia or thyroid disorders [5,6]. However, despite beneficial action, the therapy may carry side-effects, affecting both life conditions and compliance of patients in a considerable way.…”

Section: Introductionmentioning

confidence: 99%